Barry Federman
Psychiatric/Mental Health, Adult · Northampton, MANPI 1477621944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by AbbVie at 53.0% of the total.
Across 88 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$910
- Lundbeck LLC$789
- Takeda Pharmaceuticals U.S.A., Inc.$17
What the payments were for
- Food & beverage$1,715100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $910 |
| Lundbeck LLC | 29 | $789 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
How this compares
$1,715 in reported general payments places this provider in the 85th percentile of 92 psychiatric/mental health, adult providers in Massachusetts.
See all psychiatric/mental health, adult providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 60 | $3,984 |
| Aripiprazole | 16 | $2,585 |
| Bupropion XlBupropion Hcl | 58 | $2,191 |
| Clonazepam | 203 | $2,179 |
| Oxcarbazepine | 13 | $1,083 |
| Lorazepam | 97 | $893 |
| Duloxetine Hcl | 32 | $796 |
| Bupropion Hcl SrBupropion Hcl | 36 | $779 |
| Escitalopram Oxalate | 49 | $711 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 35 | $699 |
| Methylphenidate Hcl | 25 | $666 |
| Zolpidem Tartrate | 73 | $566 |
| Lamotrigine | 30 | $561 |
| Propranolol Hcl | 12 | $525 |
| Trazodone Hcl | 18 | $397 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health, adult in Northampton
- Ileana Miranda VelazNorthampton$474
- Karen ChesleyWoburn$16K
- Maria GrotzOrleans$6K
- Beverly AndersonAmesbury$5K
- Rosemarie PaoliniBrockton$5K
- Catherine JaffeArlington$4K
- Sheryl GoodallBrockton$4K
- Nimish ShahFramingham$4K
- Pamela MatthewsBourne$3K
- Meaghan RudolphMelrose$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.